{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":null,"value":72},{"name":null,"value":26},{"name":null,"value":40},{"name":null,"value":27},{"name":null,"value":80},{"name":null,"value":28},{"name":null,"value":35},{"name":null,"value":10},{"name":null,"value":134},{"name":null,"value":121},{"name":null,"value":78},{"name":null,"value":29},{"name":null,"value":32},{"name":null,"value":31},{"name":null,"value":33},{"name":null,"value":126},{"name":"Real Estate","value":36},{"name":null,"value":82},{"name":null,"value":37},{"name":null,"value":115},{"name":"Government Matters","value":"cg-2"},{"name":null,"value":1},{"name":null,"value":6},{"name":null,"value":71},{"name":null,"value":21},{"name":null,"value":23},{"name":null,"value":116},{"name":null,"value":24},{"name":null,"value":135},{"name":null,"value":25},{"name":null,"value":110},{"name":null,"value":20},{"name":null,"value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":null,"value":129},{"name":null,"value":2},{"name":null,"value":38},{"name":null,"value":3},{"name":null,"value":5},{"name":null,"value":19},{"name":null,"value":7},{"name":null,"value":4},{"name":null,"value":136},{"name":null,"value":13},{"name":null,"value":14},{"name":null,"value":15},{"name":null,"value":17},{"name":null,"value":18},{"name":null,"value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":null,"value":133},{"name":null,"value":106},{"name":null,"value":124},{"name":null,"value":111},{"name":null,"value":132},{"name":null,"value":131},{"name":null,"value":102},{"name":null,"value":125},{"name":null,"value":127},{"name":null,"value":107},{"name":null,"value":112},{"name":null,"value":105},{"name":null,"value":109},{"name":null,"value":103},{"name":null,"value":128},{"name":null,"value":123},{"name":null,"value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"21","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"D","per_page":12,"people":[{"id":442361,"version":1,"owner_type":"Person","owner_id":853,"payload":{"bio":"\u003cp\u003eTodd Davis is a partner with King \u0026amp; Spalding's Trial \u0026amp; Global Disputes practice group. For the last twenty-eight years, Mr. Davis' practice has been devoted to trying high-stakes products liability cases, including those involving medications, medical devices and consumer products.\u0026nbsp; His involvement includes cross-examining plaintiffs\u0026rsquo; key causation and medical expert witnesses at trial and in deposition. \u0026nbsp;Mr. Davis\u0026rsquo; practice\u0026nbsp;involves representing pharmaceutical and medical device companies, as well as other product manufacturers, in mass tort, consumer fraud and class action litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Davis has been recognized in Legal 500\u0026rsquo;s Product Liability and Mass Tort Defense in the Pharma and Medical Device category.\u003c/p\u003e","slug":"todd-davis","email":"tdavis@kslaw.com","phone":null,"matters":["\u003cp\u003eTrying three cases for\u0026nbsp;\u003cstrong\u003eGlaxoSmithKline\u003c/strong\u003e\u0026nbsp;in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages.\u003c/p\u003e","\u003cp\u003eTrying the first \u0026ldquo;innovator liability\u0026rdquo; prescription drug case to go to trial (\u003cem\u003eDolin v. GSK,\u0026nbsp;\u003c/em\u003e2017\u003cem\u003e).\u003c/em\u003e\u003c/p\u003e","\u003cp\u003eTrying cases for R.J. Reynolds Tobacco Company as part of the\u0026nbsp;\u003cem\u003eEngle\u003c/em\u003e-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020).\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003emedical device and pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of Paxil users under personal injury and consumer fraud theories.\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the \u0026ldquo;Big Four\u0026rdquo; federal court rulings denying class certification in pharmaceutical cases.\u0026nbsp;\u003cem\u003eSee\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn\u003c/em\u003e\u0026nbsp;\u003cem\u003ere\u003c/em\u003e\u0026nbsp;\u003cem\u003ePrempro\u003c/em\u003e\u0026nbsp;\u003cem\u003eProds. Liab. Lit.\u003c/em\u003e, 230 F.R.D. 555 (E.D. Ark. 2005).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify\u0026nbsp;\u003cstrong\u003ea statewide claim\u003c/strong\u003e\u0026nbsp;of Paxil users under California\u0026rsquo;s Unfair Competition Law, \u0026sect; 17200\u003cem\u003e.\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;218 F.R.D. 242 (C.D. Cal. 2003).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18.\u0026nbsp;\u003cem\u003ePamela Blain, et al. v. SmithKline Beecham Corp\u003c/em\u003e., 240 F.R.D. 179 (E.D. Pa. 2007).\u003c/p\u003e","\u003cp\u003eObtaining summary judgments based on federal preemption of state law\u0026nbsp;\u003cstrong\u003efailure-to-warn claims\u003c/strong\u003e\u0026nbsp;in cases involving a prescription medication.\u0026nbsp;\u003cem\u003eE.g., O\u0026rsquo;Neal v. SmithKline Beecham Corp.\u003c/em\u003e, 551 F.Supp.2d 993 (E.D. Cal. 2008);\u0026nbsp;\u003cem\u003eCandace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline\u003c/em\u003e, slip op., 2008 WL 510449 (N.D. Okla).\u003c/p\u003e","\u003cp\u003eSuccessfully excluding plaintiff\u0026rsquo;s experts\u0026rsquo; opinions that breast implants cause systemic illness on\u0026nbsp;\u003cstrong\u003e\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;grounds\u003c/strong\u003e\u0026nbsp;in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing\u0026nbsp;\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;issues in the breast implant litigation.\u0026nbsp;\u003cem\u003eAllison v. McGhan Medical Corp.\u003c/em\u003e\u0026nbsp;184 F.3d 1300 (11th Cir. 1999).\u003c/p\u003e","\u003cp\u003eSuccessfully defending\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;filed in the \u0026ldquo;rocket-docket\u0026rdquo; of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement.\u003c/p\u003e","\u003cp\u003eSuccessfully defending on appeal summary judgment for\u0026nbsp;\u003cstrong\u003ea pharmaceutical manufacturer\u003c/strong\u003e\u0026nbsp;based upon the learned intermediary doctrine.\u0026nbsp;\u003cem\u003eAllgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline\u003c/em\u003e, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008),\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d by\u003c/em\u003e\u0026nbsp;No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009),\u0026nbsp;\u003cem\u003ereh\u0026rsquo;g denied by\u003c/em\u003e\u0026nbsp;No. 08-30329 (5th Cir. May 6, 2009).\u003c/p\u003e","\u003cp\u003eObtaining summary judgment in\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;involving a prescription medication within four months after plaintiff filed his lawsuit,\u0026nbsp;\u003cem\u003eHoward v. GlaxoSmithKline\u003c/em\u003e, Case No. 05-1525 (U.S.D.C., E.D. Cal.)\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d\u003c/em\u003e\u0026nbsp;(9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs\u0026rsquo; claimed they did not timely file their lawsuit because of the defendant\u0026rsquo;s \u0026ldquo;fraudulent concealment.\u0026rdquo;\u0026nbsp;\u003cem\u003ePamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline\u003c/em\u003e, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.);\u0026nbsp;\u003cem\u003eCollins v. SmithKlineBeecham Corp.,\u003c/em\u003e\u0026nbsp;Philadelphia Court of Common Pleas, Pennsylvania,\u0026nbsp;\u003cem\u003eaff'd\u003c/em\u003e\u0026nbsp;on appeal.\u003c/p\u003e","\u003cp\u003eManaging massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs\u0026rsquo; claims.\u003c/p\u003e","\u003cp\u003eSuccessfully defending against motions to compel that sought thousands of privileged documents in\u0026nbsp;\u003cstrong\u003epersonal injury lawsuits\u003c/strong\u003e\u0026nbsp;involving prescription medications.\u003c/p\u003e","\u003cp\u003eMajor responsibility in\u0026nbsp;\u003cstrong\u003eseveral hundred breast implant cases\u003c/strong\u003e\u0026nbsp;in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict.\u003c/p\u003e","\u003cp\u003eSuccessfully arguing for\u0026nbsp;\u003cstrong\u003etransfer of a host of cases\u003c/strong\u003e\u0026nbsp;to the plaintiffs\u0026rsquo; home states under 28 U.S.C. \u0026sect; 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company\u0026rsquo;s business office as opposed to the states of their residence.)\u003c/p\u003e","\u003cp\u003eDefending\u0026nbsp;\u003cstrong\u003ehigh-ranking company executives\u003c/strong\u003e\u0026nbsp;in depositions.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea manufacturer\u003c/strong\u003e\u0026nbsp;in an emergency appeal of an order allowing plaintiffs to depose the manufacturer\u0026rsquo;s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court\u0026rsquo;s order.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":63}]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":1,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":2,"source":"smartTags"},{"id":764,"guid":"764.smart_tags","index":3,"source":"smartTags"},{"id":3,"guid":"3.capabilities","index":4,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":5,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":6,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":7,"source":"capabilities"},{"id":16,"guid":"16.capabilities","index":8,"source":"capabilities"},{"id":112,"guid":"112.capabilities","index":9,"source":"capabilities"}],"is_active":true,"last_name":"Davis","nick_name":"Todd","clerkships":[],"first_name":"Todd","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"P.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eTodd Davis is a partner with King \u0026amp; Spalding's Trial \u0026amp; Global Disputes practice group. For the last twenty-eight years, Mr. Davis' practice has been devoted to trying high-stakes products liability cases, including those involving medications, medical devices and consumer products.\u0026nbsp; His involvement includes cross-examining plaintiffs\u0026rsquo; key causation and medical expert witnesses at trial and in deposition. \u0026nbsp;Mr. Davis\u0026rsquo; practice\u0026nbsp;involves representing pharmaceutical and medical device companies, as well as other product manufacturers, in mass tort, consumer fraud and class action litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Davis has been recognized in Legal 500\u0026rsquo;s Product Liability and Mass Tort Defense in the Pharma and Medical Device category.\u003c/p\u003e","matters":["\u003cp\u003eTrying three cases for\u0026nbsp;\u003cstrong\u003eGlaxoSmithKline\u003c/strong\u003e\u0026nbsp;in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages.\u003c/p\u003e","\u003cp\u003eTrying the first \u0026ldquo;innovator liability\u0026rdquo; prescription drug case to go to trial (\u003cem\u003eDolin v. GSK,\u0026nbsp;\u003c/em\u003e2017\u003cem\u003e).\u003c/em\u003e\u003c/p\u003e","\u003cp\u003eTrying cases for R.J. Reynolds Tobacco Company as part of the\u0026nbsp;\u003cem\u003eEngle\u003c/em\u003e-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020).\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003emedical device and pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of Paxil users under personal injury and consumer fraud theories.\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the \u0026ldquo;Big Four\u0026rdquo; federal court rulings denying class certification in pharmaceutical cases.\u0026nbsp;\u003cem\u003eSee\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn\u003c/em\u003e\u0026nbsp;\u003cem\u003ere\u003c/em\u003e\u0026nbsp;\u003cem\u003ePrempro\u003c/em\u003e\u0026nbsp;\u003cem\u003eProds. Liab. Lit.\u003c/em\u003e, 230 F.R.D. 555 (E.D. Ark. 2005).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify\u0026nbsp;\u003cstrong\u003ea statewide claim\u003c/strong\u003e\u0026nbsp;of Paxil users under California\u0026rsquo;s Unfair Competition Law, \u0026sect; 17200\u003cem\u003e.\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;218 F.R.D. 242 (C.D. Cal. 2003).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18.\u0026nbsp;\u003cem\u003ePamela Blain, et al. v. SmithKline Beecham Corp\u003c/em\u003e., 240 F.R.D. 179 (E.D. Pa. 2007).\u003c/p\u003e","\u003cp\u003eObtaining summary judgments based on federal preemption of state law\u0026nbsp;\u003cstrong\u003efailure-to-warn claims\u003c/strong\u003e\u0026nbsp;in cases involving a prescription medication.\u0026nbsp;\u003cem\u003eE.g., O\u0026rsquo;Neal v. SmithKline Beecham Corp.\u003c/em\u003e, 551 F.Supp.2d 993 (E.D. Cal. 2008);\u0026nbsp;\u003cem\u003eCandace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline\u003c/em\u003e, slip op., 2008 WL 510449 (N.D. Okla).\u003c/p\u003e","\u003cp\u003eSuccessfully excluding plaintiff\u0026rsquo;s experts\u0026rsquo; opinions that breast implants cause systemic illness on\u0026nbsp;\u003cstrong\u003e\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;grounds\u003c/strong\u003e\u0026nbsp;in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing\u0026nbsp;\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;issues in the breast implant litigation.\u0026nbsp;\u003cem\u003eAllison v. McGhan Medical Corp.\u003c/em\u003e\u0026nbsp;184 F.3d 1300 (11th Cir. 1999).\u003c/p\u003e","\u003cp\u003eSuccessfully defending\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;filed in the \u0026ldquo;rocket-docket\u0026rdquo; of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement.\u003c/p\u003e","\u003cp\u003eSuccessfully defending on appeal summary judgment for\u0026nbsp;\u003cstrong\u003ea pharmaceutical manufacturer\u003c/strong\u003e\u0026nbsp;based upon the learned intermediary doctrine.\u0026nbsp;\u003cem\u003eAllgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline\u003c/em\u003e, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008),\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d by\u003c/em\u003e\u0026nbsp;No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009),\u0026nbsp;\u003cem\u003ereh\u0026rsquo;g denied by\u003c/em\u003e\u0026nbsp;No. 08-30329 (5th Cir. May 6, 2009).\u003c/p\u003e","\u003cp\u003eObtaining summary judgment in\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;involving a prescription medication within four months after plaintiff filed his lawsuit,\u0026nbsp;\u003cem\u003eHoward v. GlaxoSmithKline\u003c/em\u003e, Case No. 05-1525 (U.S.D.C., E.D. Cal.)\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d\u003c/em\u003e\u0026nbsp;(9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs\u0026rsquo; claimed they did not timely file their lawsuit because of the defendant\u0026rsquo;s \u0026ldquo;fraudulent concealment.\u0026rdquo;\u0026nbsp;\u003cem\u003ePamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline\u003c/em\u003e, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.);\u0026nbsp;\u003cem\u003eCollins v. SmithKlineBeecham Corp.,\u003c/em\u003e\u0026nbsp;Philadelphia Court of Common Pleas, Pennsylvania,\u0026nbsp;\u003cem\u003eaff'd\u003c/em\u003e\u0026nbsp;on appeal.\u003c/p\u003e","\u003cp\u003eManaging massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs\u0026rsquo; claims.\u003c/p\u003e","\u003cp\u003eSuccessfully defending against motions to compel that sought thousands of privileged documents in\u0026nbsp;\u003cstrong\u003epersonal injury lawsuits\u003c/strong\u003e\u0026nbsp;involving prescription medications.\u003c/p\u003e","\u003cp\u003eMajor responsibility in\u0026nbsp;\u003cstrong\u003eseveral hundred breast implant cases\u003c/strong\u003e\u0026nbsp;in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict.\u003c/p\u003e","\u003cp\u003eSuccessfully arguing for\u0026nbsp;\u003cstrong\u003etransfer of a host of cases\u003c/strong\u003e\u0026nbsp;to the plaintiffs\u0026rsquo; home states under 28 U.S.C. \u0026sect; 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company\u0026rsquo;s business office as opposed to the states of their residence.)\u003c/p\u003e","\u003cp\u003eDefending\u0026nbsp;\u003cstrong\u003ehigh-ranking company executives\u003c/strong\u003e\u0026nbsp;in depositions.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea manufacturer\u003c/strong\u003e\u0026nbsp;in an emergency appeal of an order allowing plaintiffs to depose the manufacturer\u0026rsquo;s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court\u0026rsquo;s order.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":805}]},"capability_group_id":3},"created_at":"2025-11-05T05:03:30.000Z","updated_at":"2025-11-05T05:03:30.000Z","searchable_text":"Davis{{ FIELD }}Trying three cases for GlaxoSmithKline in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages.{{ FIELD }}Trying the first “innovator liability” prescription drug case to go to trial (Dolin v. GSK, 2017).{{ FIELD }}Trying cases for R.J. Reynolds Tobacco Company as part of the Engle-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020).{{ FIELD }}Representing medical device and pharmaceutical companies in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a nationwide class of Paxil users under personal injury and consumer fraud theories. In re Paxil, 212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the “Big Four” federal court rulings denying class certification in pharmaceutical cases. See In re Prempro Prods. Liab. Lit., 230 F.R.D. 555 (E.D. Ark. 2005).{{ FIELD }}Defeating efforts to certify a statewide claim of Paxil users under California’s Unfair Competition Law, § 17200. In re Paxil, 218 F.R.D. 242 (C.D. Cal. 2003).{{ FIELD }}Defeating efforts to certify a nationwide class of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18. Pamela Blain, et al. v. SmithKline Beecham Corp., 240 F.R.D. 179 (E.D. Pa. 2007).{{ FIELD }}Obtaining summary judgments based on federal preemption of state law failure-to-warn claims in cases involving a prescription medication. E.g., O’Neal v. SmithKline Beecham Corp., 551 F.Supp.2d 993 (E.D. Cal. 2008); Candace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline, slip op., 2008 WL 510449 (N.D. Okla).{{ FIELD }}Successfully excluding plaintiff’s experts’ opinions that breast implants cause systemic illness on Daubert grounds in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing Daubert issues in the breast implant litigation. Allison v. McGhan Medical Corp. 184 F.3d 1300 (11th Cir. 1999).{{ FIELD }}Successfully defending a product liability lawsuit filed in the “rocket-docket” of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement.{{ FIELD }}Successfully defending on appeal summary judgment for a pharmaceutical manufacturer based upon the learned intermediary doctrine. Allgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008), aff’d by No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009), reh’g denied by No. 08-30329 (5th Cir. May 6, 2009).{{ FIELD }}Obtaining summary judgment in a product liability lawsuit involving a prescription medication within four months after plaintiff filed his lawsuit, Howard v. GlaxoSmithKline, Case No. 05-1525 (U.S.D.C., E.D. Cal.) aff’d (9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs’ claimed they did not timely file their lawsuit because of the defendant’s “fraudulent concealment.” Pamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.); Collins v. SmithKlineBeecham Corp., Philadelphia Court of Common Pleas, Pennsylvania, aff'd on appeal.{{ FIELD }}Managing massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs’ claims.{{ FIELD }}Successfully defending against motions to compel that sought thousands of privileged documents in personal injury lawsuits involving prescription medications.{{ FIELD }}Major responsibility in several hundred breast implant cases in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict.{{ FIELD }}Successfully arguing for transfer of a host of cases to the plaintiffs’ home states under 28 U.S.C. § 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company’s business office as opposed to the states of their residence.){{ FIELD }}Defending high-ranking company executives in depositions.{{ FIELD }}Representing a manufacturer in an emergency appeal of an order allowing plaintiffs to depose the manufacturer’s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court’s order.{{ FIELD }}Todd Davis is a partner with King \u0026amp; Spalding's Trial \u0026amp; Global Disputes practice group. For the last twenty-eight years, Mr. Davis' practice has been devoted to trying high-stakes products liability cases, including those involving medications, medical devices and consumer products.  His involvement includes cross-examining plaintiffs’ key causation and medical expert witnesses at trial and in deposition.  Mr. Davis’ practice involves representing pharmaceutical and medical device companies, as well as other product manufacturers, in mass tort, consumer fraud and class action litigation.\nMr. Davis has been recognized in Legal 500’s Product Liability and Mass Tort Defense in the Pharma and Medical Device category. Todd P Davis Partner Stetson University Stetson University College of Law Mercer University Mercer University Walter F. George School of Law U.S. Court of Appeals for the Fifth Circuit U.S. Court of Appeals for the Sixth Circuit U.S. Court of Appeals for the Ninth Circuit U.S. Court of Appeals for the Tenth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the Middle District of Florida U.S. District Court for the Middle District of Georgia U.S. District Court for the Northern District of Georgia U.S. District Court for the Southern District of Georgia Florida Georgia American Bar Association State Bar of Georgia Atlanta Bar Association The Florida Bar Sixth and Eleventh Circuit Court of Appeals Trying three cases for GlaxoSmithKline in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages. Trying the first “innovator liability” prescription drug case to go to trial (Dolin v. GSK, 2017). Trying cases for R.J. Reynolds Tobacco Company as part of the Engle-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020). Representing medical device and pharmaceutical companies in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a nationwide class of Paxil users under personal injury and consumer fraud theories. In re Paxil, 212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the “Big Four” federal court rulings denying class certification in pharmaceutical cases. See In re Prempro Prods. Liab. Lit., 230 F.R.D. 555 (E.D. Ark. 2005). Defeating efforts to certify a statewide claim of Paxil users under California’s Unfair Competition Law, § 17200. In re Paxil, 218 F.R.D. 242 (C.D. Cal. 2003). Defeating efforts to certify a nationwide class of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18. Pamela Blain, et al. v. SmithKline Beecham Corp., 240 F.R.D. 179 (E.D. Pa. 2007). Obtaining summary judgments based on federal preemption of state law failure-to-warn claims in cases involving a prescription medication. E.g., O’Neal v. SmithKline Beecham Corp., 551 F.Supp.2d 993 (E.D. Cal. 2008); Candace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline, slip op., 2008 WL 510449 (N.D. Okla). Successfully excluding plaintiff’s experts’ opinions that breast implants cause systemic illness on Daubert grounds in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing Daubert issues in the breast implant litigation. Allison v. McGhan Medical Corp. 184 F.3d 1300 (11th Cir. 1999). Successfully defending a product liability lawsuit filed in the “rocket-docket” of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement. Successfully defending on appeal summary judgment for a pharmaceutical manufacturer based upon the learned intermediary doctrine. Allgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008), aff’d by No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009), reh’g denied by No. 08-30329 (5th Cir. May 6, 2009). Obtaining summary judgment in a product liability lawsuit involving a prescription medication within four months after plaintiff filed his lawsuit, Howard v. GlaxoSmithKline, Case No. 05-1525 (U.S.D.C., E.D. Cal.) aff’d (9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs’ claimed they did not timely file their lawsuit because of the defendant’s “fraudulent concealment.” Pamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.); Collins v. SmithKlineBeecham Corp., Philadelphia Court of Common Pleas, Pennsylvania, aff'd on appeal. Managing massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs’ claims. Successfully defending against motions to compel that sought thousands of privileged documents in personal injury lawsuits involving prescription medications. Major responsibility in several hundred breast implant cases in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict. Successfully arguing for transfer of a host of cases to the plaintiffs’ home states under 28 U.S.C. § 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company’s business office as opposed to the states of their residence.) Defending high-ranking company executives in depositions. Representing a manufacturer in an emergency appeal of an order allowing plaintiffs to depose the manufacturer’s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court’s order.","searchable_name":"Todd P. Davis","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":444001,"version":1,"owner_type":"Person","owner_id":7205,"payload":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","slug":"robert-deconti","email":"rdeconti@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"DeConti","nick_name":"Rob","clerkships":[],"first_name":"Robert","title_rank":9999,"updated_by":202,"law_schools":[{"id":3042,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1999-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"K.","name_suffix":"","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}],"linked_in_url":"https://www.linkedin.com/in/robertdeconti","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12841}]},"capability_group_id":2},"created_at":"2025-12-05T05:02:32.000Z","updated_at":"2025-12-05T05:02:32.000Z","searchable_text":"DeConti{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Distinguished Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Meritorious Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Award for Fighting Fraud, Waste, and Abuse\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"President’s Council on Integrity and Efficiency Award for Excellence\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Office of Inspector General Cooperative Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Exceptional Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}Rob DeConti is a partner in King \u0026amp; Spalding’s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG’s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government’s enforcement and compliance priorities. \nWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government’s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG’s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government’s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG’s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\nBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG’s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG’s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide. \nPrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\nIn 2007, Rob served as a Special Trial Attorney in DOJ’s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel’s office at a managed care organization. Partner HHS Secretary’s Award for Distinguished Service  HHS Secretary’s Award for Meritorious Service  Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)  Inspector General’s Award for Fighting Fraud, Waste, and Abuse  President’s Council on Integrity and Efficiency Award for Excellence  Office of Inspector General Cooperative Achievement Award (multiple awards)  Inspector General’s Exceptional Achievement Award (multiple awards)  University of Virginia  American University Washington College of Law American University Washington College of Law District of Columbia Virginia Virginia State Bar American Health Law Association Government Attorney-at-Large, American Bar Association Health Law Section Council, 2022-2025 Government Liaison to the Health Care Compliance Association, Board of Directors, 2008-2012","searchable_name":"Robert K. DeConti (Rob)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":431883,"version":1,"owner_type":"Person","owner_id":3969,"payload":{"bio":"\u003cp\u003eA partner in our FDA and Life Sciences practice, Lisa has almost 25\u0026nbsp;years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco). \u0026nbsp;She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner\u0026rsquo;s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency\u0026rsquo;s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\u003c/p\u003e\n\u003cp\u003eLisa is a frequent author and speaker on topics including:\u0026nbsp; digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women\u0026rsquo;s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her \u0026ldquo;unending enthusiasm to take on client\u0026rsquo;s causes as her own.\"\u003c/p\u003e","slug":"lisa-dwyer","email":"ldwyer@kslaw.com","phone":null,"matters":["\u003cp\u003eFocus on Digital Health/Telehealth\u003c/p\u003e","\u003cp\u003eFocus on In Vitro Diagnostic Tests and Laboratory Developed Tests\u003c/p\u003e","\u003cp\u003eFDA/FTC regulation of advertising and promotion\u003c/p\u003e","\u003cp\u003ePre-market development (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eFDA product submissions (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eDevelops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\u003c/p\u003e\n\u003cp\u003e- Lanham Act\u003c/p\u003e\n\u003cp\u003e- Unfair trade practice statutes (state and federal)\u003c/p\u003e","\u003cp\u003eEngages FDA and Congress on key issues related to FDA-regulated products\u003c/p\u003e","\u003cp\u003eResponds to FDA/FTC inquires, FDA warning letters, and FDA 483s\u003c/p\u003e","\u003cp\u003eExperience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics\u003c/p\u003e","\u003cp\u003eCo-Chairs Women's Health Initiative\u003c/p\u003e","\u003cp\u003eMember of Cannabis Steering Committee\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":53}]},"expertise":[{"id":2,"guid":"2.capabilities","index":0,"source":"capabilities"},{"id":3,"guid":"3.smart_tags","index":1,"source":"smartTags"},{"id":23,"guid":"23.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":5,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":6,"source":"smartTags"},{"id":112,"guid":"112.capabilities","index":7,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":8,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":9,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":10,"source":"smartTags"},{"id":1206,"guid":"1206.smart_tags","index":11,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":12,"source":"smartTags"},{"id":133,"guid":"133.capabilities","index":13,"source":"capabilities"}],"is_active":true,"last_name":"Dwyer","nick_name":"Lisa","clerkships":[],"first_name":"Lisa","title_rank":9999,"updated_by":202,"law_schools":[{"id":753,"meta":{"degree":"J.D.","honors":"honors","is_law_school":"1","graduation_date":"1998-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"M.","name_suffix":"","recognitions":[{"title":"Next Generation Lawyer","detail":"Legal 500, 2017 and 2019"},{"title":"Recognition for Government Relations ","detail":"Legal 500, 2016"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests ","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule ","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, FDA Language Access Plan Working Group","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)","detail":"FDA Award Ceremony, 2012"},{"title":"FDA Group Recognition Award, Menu Labeling Working Group","detail":"CFSAN/FDA Award Ceremony, 2011"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eA partner in our FDA and Life Sciences practice, Lisa has almost 25\u0026nbsp;years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco). \u0026nbsp;She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner\u0026rsquo;s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency\u0026rsquo;s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\u003c/p\u003e\n\u003cp\u003eLisa is a frequent author and speaker on topics including:\u0026nbsp; digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women\u0026rsquo;s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her \u0026ldquo;unending enthusiasm to take on client\u0026rsquo;s causes as her own.\"\u003c/p\u003e","matters":["\u003cp\u003eFocus on Digital Health/Telehealth\u003c/p\u003e","\u003cp\u003eFocus on In Vitro Diagnostic Tests and Laboratory Developed Tests\u003c/p\u003e","\u003cp\u003eFDA/FTC regulation of advertising and promotion\u003c/p\u003e","\u003cp\u003ePre-market development (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eFDA product submissions (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eDevelops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\u003c/p\u003e\n\u003cp\u003e- Lanham Act\u003c/p\u003e\n\u003cp\u003e- Unfair trade practice statutes (state and federal)\u003c/p\u003e","\u003cp\u003eEngages FDA and Congress on key issues related to FDA-regulated products\u003c/p\u003e","\u003cp\u003eResponds to FDA/FTC inquires, FDA warning letters, and FDA 483s\u003c/p\u003e","\u003cp\u003eExperience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics\u003c/p\u003e","\u003cp\u003eCo-Chairs Women's Health Initiative\u003c/p\u003e","\u003cp\u003eMember of Cannabis Steering Committee\u003c/p\u003e"],"recognitions":[{"title":"Next Generation Lawyer","detail":"Legal 500, 2017 and 2019"},{"title":"Recognition for Government Relations ","detail":"Legal 500, 2016"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests ","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule ","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, FDA Language Access Plan Working Group","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)","detail":"FDA Award Ceremony, 2012"},{"title":"FDA Group Recognition Award, Menu Labeling Working Group","detail":"CFSAN/FDA Award Ceremony, 2011"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11487}]},"capability_group_id":2},"created_at":"2025-07-09T20:54:25.000Z","updated_at":"2025-07-09T20:54:25.000Z","searchable_text":"Dwyer{{ FIELD }}{:title=\u0026gt;\"Next Generation Lawyer\", :detail=\u0026gt;\"Legal 500, 2017 and 2019\"}{{ FIELD }}{:title=\u0026gt;\"Recognition for Government Relations \", :detail=\u0026gt;\"Legal 500, 2016\"}{{ FIELD }}{:title=\u0026gt;\"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests \", :detail=\u0026gt;\"FDA Award Ceremony, 2015\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document\", :detail=\u0026gt;\"FDA Award Ceremony, 2015\"}{{ FIELD }}{:title=\u0026gt;\"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule \", :detail=\u0026gt;\"FDA Award Ceremony, 2014\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, FDA Language Access Plan Working Group\", :detail=\u0026gt;\"FDA Award Ceremony, 2014\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)\", :detail=\u0026gt;\"FDA Award Ceremony, 2012\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Menu Labeling Working Group\", :detail=\u0026gt;\"CFSAN/FDA Award Ceremony, 2011\"}{{ FIELD }}Focus on Digital Health/Telehealth{{ FIELD }}Focus on In Vitro Diagnostic Tests and Laboratory Developed Tests{{ FIELD }}FDA/FTC regulation of advertising and promotion{{ FIELD }}Pre-market development (drugs and devices (including digital health products)){{ FIELD }}FDA product submissions (drugs and devices (including digital health products)){{ FIELD }}Develops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\n- Lanham Act\n- Unfair trade practice statutes (state and federal){{ FIELD }}Engages FDA and Congress on key issues related to FDA-regulated products{{ FIELD }}Responds to FDA/FTC inquires, FDA warning letters, and FDA 483s{{ FIELD }}Experience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics{{ FIELD }}Co-Chairs Women's Health Initiative{{ FIELD }}Member of Cannabis Steering Committee{{ FIELD }}A partner in our FDA and Life Sciences practice, Lisa has almost 25 years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco).  She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.\nPreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner’s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency’s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\nLisa is a frequent author and speaker on topics including:  digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women’s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her “unending enthusiasm to take on client’s causes as her own.\" Lisa M Dwyer Partner Next Generation Lawyer Legal 500, 2017 and 2019 Recognition for Government Relations  Legal 500, 2016 FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests  FDA Award Ceremony, 2015 FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document FDA Award Ceremony, 2015 FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule  FDA Award Ceremony, 2014 FDA Group Recognition Award, FDA Language Access Plan Working Group FDA Award Ceremony, 2014 FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader) FDA Award Ceremony, 2012 FDA Group Recognition Award, Menu Labeling Working Group CFSAN/FDA Award Ceremony, 2011 Wesleyan University  George Washington University George Washington University Law School District of Columbia Massachusetts Pennsylvania Focus on Digital Health/Telehealth Focus on In Vitro Diagnostic Tests and Laboratory Developed Tests FDA/FTC regulation of advertising and promotion Pre-market development (drugs and devices (including digital health products)) FDA product submissions (drugs and devices (including digital health products)) Develops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\n- Lanham Act\n- Unfair trade practice statutes (state and federal) Engages FDA and Congress on key issues related to FDA-regulated products Responds to FDA/FTC inquires, FDA warning letters, and FDA 483s Experience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics Co-Chairs Women's Health Initiative Member of Cannabis Steering Committee","searchable_name":"Lisa M. Dwyer","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426488,"version":1,"owner_type":"Person","owner_id":3854,"payload":{"bio":"\u003cp\u003eKalle Deyette is a\u0026nbsp;senior associate\u0026nbsp;in King \u0026amp; Spalding\u0026rsquo;s Washington, D.C., office and is a member of the FDA and Life Sciences practice.\u0026nbsp; Kalle focuses her practice on the regulation of medical devices and pharmaceutical manufacturers, as well as healthcare providers and suppliers.\u0026nbsp; Her expertise is concentrated on healthcare fraud and abuse and compliance, including analyzing arrangements under the Anti-Kickback Statute and assisting with government investigations and internal investigations into alleged violations of company policy and federal law. \u0026nbsp;Kalle also provides counsel to both the Ad Hoc State Law Compliance Group on a variety of laws and regulations, including state transparency and disclosure laws, and the International Marketing and Disclosure Compliance Group on a variety of international laws, regulations, and industry codes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKalle graduated from Saint Louis University School of Law, where she served as the Notes and Comments editor of the Saint Louis University Journal of Health Law \u0026amp; Policy.\u003c/p\u003e","slug":"kalle-deyette","email":"kdeyette@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":21,"guid":"21.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"}],"is_active":true,"last_name":"Deyette","nick_name":"Kalle","clerkships":[],"first_name":"Kalle","title_rank":9999,"updated_by":101,"law_schools":[{"id":1732,"meta":{"degree":"J.D.","honors":"magna cum laude","is_law_school":1,"graduation_date":"2015-01-01 00:00:00 UTC"},"order":0,"pin_order":null,"pin_expiration":null}],"middle_name":"E.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":75,"translated_fields":{"en":{"bio":"\u003cp\u003eKalle Deyette is a\u0026nbsp;senior associate\u0026nbsp;in King \u0026amp; Spalding\u0026rsquo;s Washington, D.C., office and is a member of the FDA and Life Sciences practice.\u0026nbsp; Kalle focuses her practice on the regulation of medical devices and pharmaceutical manufacturers, as well as healthcare providers and suppliers.\u0026nbsp; Her expertise is concentrated on healthcare fraud and abuse and compliance, including analyzing arrangements under the Anti-Kickback Statute and assisting with government investigations and internal investigations into alleged violations of company policy and federal law. \u0026nbsp;Kalle also provides counsel to both the Ad Hoc State Law Compliance Group on a variety of laws and regulations, including state transparency and disclosure laws, and the International Marketing and Disclosure Compliance Group on a variety of international laws, regulations, and industry codes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKalle graduated from Saint Louis University School of Law, where she served as the Notes and Comments editor of the Saint Louis University Journal of Health Law \u0026amp; Policy.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":816}]},"capability_group_id":2},"created_at":"2025-05-26T04:53:46.000Z","updated_at":"2025-05-26T04:53:46.000Z","searchable_text":"Deyette{{ FIELD }}Kalle Deyette is a senior associate in King \u0026amp; Spalding’s Washington, D.C., office and is a member of the FDA and Life Sciences practice.  Kalle focuses her practice on the regulation of medical devices and pharmaceutical manufacturers, as well as healthcare providers and suppliers.  Her expertise is concentrated on healthcare fraud and abuse and compliance, including analyzing arrangements under the Anti-Kickback Statute and assisting with government investigations and internal investigations into alleged violations of company policy and federal law.  Kalle also provides counsel to both the Ad Hoc State Law Compliance Group on a variety of laws and regulations, including state transparency and disclosure laws, and the International Marketing and Disclosure Compliance Group on a variety of international laws, regulations, and industry codes.\nKalle graduated from Saint Louis University School of Law, where she served as the Notes and Comments editor of the Saint Louis University Journal of Health Law \u0026amp; Policy. Senior Associate Saint Louis University Saint Louis University School of Law Saint Louis University Saint Louis University School of Law District of Columbia Missouri","searchable_name":"Kalle E. Deyette","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null}]}}